第五版世界卫生组织造血淋巴组织肿瘤分类:髓系肿瘤解读
本文综述第五版WHO造血淋巴组织肿瘤分类(WHO-HEM5)中髓系肿瘤的更新,重点比较与修订第四版(WHO-HEM4R)的变化。分类基于病理学家、临床医生和遗传学家 multidisciplinary 共识,采用分层结构,强调遗传和分子驱动因素。最显著更新在急性髓系白血病和骨髓增生异常肿瘤(原骨髓增生异常综合征)部分,纳入新的疾病定义性遗传改变。
要点
- WHO-HEM5髓系肿瘤分类强调遗传和分子驱动因素,更新了急性髓系白血病和骨髓增生异常肿瘤的定义。
- 新分类采用分层结构,允许在部分满足诊断标准或未完成全面检查时使用家族(类)级别定义。
- 综述对比WHO-HEM4R与WHO-HEM5,指导新分类在常规实践中的诊断应用。
核心结论
- WHO-HEM5对髓系肿瘤分类进行了重大更新,增加对遗传和分子驱动因素的重视,最显著变化在急性髓系白血病和骨髓增生异常肿瘤部分。
研究设计与样本
- 综述性文章,由病理学家、临床医生和遗传学家 multidisciplinary 参与制定,比较WHO-HEM5与WHO-HEM4R的髓系肿瘤分类变化。
主要发现
- 与WHO-HEM4R相比,WHO-HEM5中髓系肿瘤的疾病类型和亚型有所扩展,主要由于基因组知识的扩展。
- 修订分类采用分层结构,允许在部分满足诊断标准或未完成全面检查时使用家族(类)级别定义。
- 最显著的变化应用于急性髓系白血病和骨髓增生异常肿瘤(原骨髓增生异常综合征)部分,纳入了新的疾病定义性遗传改变。
关键数值与推荐
- WHO-HEM5髓系肿瘤分类基于病理学家、临床医生和遗传学家的 multidisciplinary 方法。
- 分类采用分层结构,允许在定义诊断标准部分满足或未完成全面检查时使用家族(类)级别定义。
- 急性髓系白血病和骨髓增生异常肿瘤部分纳入了新的疾病定义性遗传改变。
临床怎么用
- 新分类可应用于常规实践中髓系肿瘤的诊断,强调遗传和分子驱动因素。
- 分层结构允许在部分满足诊断标准或未完成全面检查时使用家族(类)级别定义,提供诊断灵活性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this manuscript, we review myeloid neoplasms in the fifth edition of the World Health Organization classification of hematolymphoid tumors (WHO-HEM5), focusing on changes from the revised fourth edition (WHO-HEM4R). Disease types and subtypes have expanded compared with WHO-HEM4R, mainly because of the expansion in genomic knowledge of these diseases. The revised classification is based on a multidisciplinary approach including input from a large body of pathologists, clinicians, and geneticists. The revised classification follows a hierarchical structure allowing usage of family (class)-level definitions where the defining diagnostic criteria are partially met or a complete investigational workup has not been possible. Overall, the WHO-HEM5 revisions to the classification of myeloid neoplasms include major updates and revisions with increased emphasis on genetic and molecular drivers of disease. The most notable changes have been applied to the sections of acute myeloid leukemia and myelodysplastic neoplasms (previously referred to as myelodysplastic syndrome) with incorporation of novel, disease-defining genetic changes. In this review we focus on highlighting the updates in the classification of myeloid neoplasms, providing a comparison with WHO-HEM4R, and offering guidance on how the new classification can be applied to the diagnosis of myeloid neoplasms in routine practice.
引用
- Loghavi S, Kanagal-Shamanna R, Khoury JD, et al. Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms. Mod Pathol. 2023. PMID: 38043791. doi:10.1016/j.modpat.2023.100397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。